RNAZ (TransCode Therapeutics) Gross Margin % : 0.00% (As of Sep. 2024)

TransCode Therapeutics Gross Margin % Chart

TransCode Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Gross Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of TransCode Therapeutics's Gross Margin %

For the Biotechnology subindustry, TransCode Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TransCode Therapeutics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where TransCode Therapeutics's Gross Margin % falls into.

TransCode Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

TransCode Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

TransCode Therapeutics's Gross Margin for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

TransCode Therapeutics  (NAS:RNAZ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

TransCode Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

TransCode Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of TransCode Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

TransCode Therapeutics Business Description